Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2002 Oct;3(10):1517-26.

Irofulven (MGI Pharma).

Author information

  • 1The Norwegian Radium Hospital, Oslo. mark.baekelandt@klinmed.uio.no

Abstract

MGI Pharma is developing irofulven, a semi-synthetic compound derived from illudin S, a toxin from the Omphalotus illudens mushroom, for the potential treatment of refractory and relapsed tumors, including ovarian, prostate, hepatocellular, breast, lung and colon cancers. Phase II trials of the compound as a monotherapy or in combination therapies are ongoing for a number of these indications.

PMID:
12431030
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk